SW
TEVA icon

SVB Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

SVB Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,472
Closed -$348K – 481
2017
Q2 		$348K Buy
10,472
+1,871
+22% +$57.9K 0.01% 388
2017
Q1 		$276K Buy
8,601
+2,895
+51% +$98.8K 0.01% 419
2016
Q4 		$207K Sell
5,706
-1,086
-16% -$43.4K 0.01% 466
2016
Q3 		$312K Sell
6,792
-1,187
-15% -$61.9K 0.01% 429
2016
Q2 		$401K Sell
7,979
-1,743
-18% -$92.8K 0.02% 385
2016
Q1 		$520K Sell
9,722
-566
-6% -$33.2K 0.02% 342
2015
Q4 		$675K Sell
10,288
-726
-7% -$44.9K 0.03% 326
2015
Q3 		$622K Sell
11,014
-292
-3% -$18.9K 0.02% 369
2015
Q2 		$668K Sell
11,306
-22,457
-67% -$1.39M 0.02% 382
2015
Q1 		$2.1M Sell
33,763
-170
-0.5% -$9.88K 0.07% 229
2014
Q4 		$1.95M Buy
+33,933
New +$1.89M 0.06% 239

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

SVB Wealth's TEVA Position: Q3 2017 in Review

SVB Wealth sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 10,472 shares — an estimated $348K sold.

SVB Wealth first reported a position in TEVA in Q4 2014 and held it in 11 quarters. The position peaked at $2.1M in Q1 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • SVB Wealth reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • SVB Wealth sold 10,472 Teva Pharmaceuticals shares in Q3 2017, an estimated $348K.
  • SVB Wealth first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 11 quarters.
  • SVB Wealth's Teva Pharmaceuticals position peaked at $2.1M in Q1 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on SVB Wealth's 13F filing for Q3 2017, filed 13 Nov 2017.